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Impact of S-sulfocysteine on fragments and trisulfide bond 
linkages in monoclonal antibodies
Ronja Seibel1, Sandra Maier2, Alisa Schnellbaecher1, Susanne Bohl1, Maria Wehsling1, Anne Zeck2, Aline Zimmer1
Introduction
The quality of recombinant proteins such as monoclonal antibodies
produced using Chinese hamster ovary (CHO) cell-based mammalian
systems is dependent on many factors, including cell line, process and
cell culture media. Due to these factors, the generated product is
heterogeneous and may present chemically induced modifications or
post-translational modifications that affect antibody stability,
functionality and, in some cases, patient safety.
This study demonstrates that S-sulfocysteine, a cysteine derivative,
can increase the cell specific productivity in cell lines cultivated with
different processes while minimizing trisulfide linkages in generated
mAbs, mainly between heavy and light chain. The supplementation of
a cell culture feed with S-sulfocysteine also proved to be useful to
reduce the percentage of antibody fragments generated from the
monoclonal antibody. Overall, this new component used in the
upstream process allows a reduction of product heterogeneity.
Results
Four suspension CHO cell lines engineered to produce human
monoclonal IgG1 antibodies were cultivated using different fed-batch
processes. In the control condition, cysteine was added throughout the
process using a cysteine-containing feed. In the second condition,
cysteine was allowed to interact with pyruvate or α-ketoglutarate in the
feed, allowing formation of the thiazolidines CP or CKG respectively1.
These condensation products can stabilize cell culture media
formulations containing cysteine2 and have been described as a tool to
reduce trisulfide bond formation in IgG3. They were used in this study
as positive control. In the third condition, the cysteine present in the
feed was replaced by SSC. This molecule has been described previously
as a potent cysteine derivative having an anti-oxidative effect in CHO-
based fed-batch processes4.
Whereas the cell specific productivity (Qp) was only significantly
increased for CP with cell line 1, the Qp was significantly increased in
the SSC containing process for three cell lines producing different
mAbs (Mann-Whitney test). This indicates that SSC can robustly
increase Qp in different CHO cell lines or processes.
The starting relative percentage of trisulfide bonds was different for
each antibody ranging from 11% to 46%. The use of SSC-containing
processes allowed a drastic reduction of the trisulfide bond levels to
values below 5%. The effect of SSC was always stronger when
compared to the thiazolidine control. Finally, the use of a SSC-
containing feed decreased the occurrence of low molecular weight
(LMW) fragments with a concomitant increase in the main intact IgG,
confirming the positive correlation between trisulfide bonds and
fragmentation proposed by Liu et al5.
Conclusion
Altogether, our results indicate that SSC can be used in cell culture
processes to reduce mAb heterogeneity, in particular to decrease the
amount of trisulfide bonds and fragments. This cysteine derivative may
also be used to develop neutral pH feeds and to increase cell specific
productivity while reducing the overall IgG heterogeneity6.
Materials and Methods
1 MilliporeSigma, Upstream R&D, Advanced Cell Culture Technologies, Frankfurter Str. 250, Darmstadt, Germany













Disulfide bond : Cys-S-S-Cys
Trisulfide bond : Cys-S-S-S-Cys
Cell culture conditions :
IgG fragmentation : Fragments were separated according to their
size in non-reduced conditions using capillary gel electrophoresis with
SDS (CE-SDS) and the Beckman Coulter IgG Purity / Heterogeneity
assay. 100 µg of IgG were alkylated using 12.5 mM iodoacetamide,
denatured 10 min at 70°C 500 rpm and separated using 50 µm fused
silica capillary on a CESI 8000 instrument.
Trisulfide bond characterization: Trisulfide bonds were
characterized using nano LC-MS after alkylation (NEM) and Lys-C /
trypsin cleavage. The separation was performed on a HSS T3 column
(Waters) and the analysis was performed using a Q-Exactive Plus
mass spectrometer.
1 Wlodek, L., Acta Biochim Pol, 1988. 35(4): p. 307-17
2 Kuschelewski, J. et al., Biotech Prog 2017. 33(3): p. 759-770
3 Kshirsagar, R. and A. Gilbert, WO2012/158551
4 Hecklau, C. et al., J Biotechnol, 2016. 218: p. 53-63
5 Liu, R. et al., MAbs, 2017. 9(3): p. 490-497
6 Seibel, R. et al., MAbs, 2017. 9(6): p. 889-897









37 °C (day 0 - day 5), 33°C (day 
5-21), pH 6.95 ± 0.15, 50 % 
dissolved oxygen, agitation 140 
rpm
2.105
Main feed: 3% (day 3), 6% (days 5, 7, 9, 
14)
Glucose adjusted on demand to 6 g/L





37 °C, pH 7.0 ± 0.02, 50 % 
dissolved oxygen, agitation 140 
rpm
2.105
Main feed: 3% (day 3, 5), 6% (day 7), 3% 
(day 10, 12))
Glucose adjusted on demand to 6 g/L
mAb2 CHO-K1 IgG1 Process 2
CellventoTM 
CHO-220
50 mL spin 
tubes
37 °C, 5% CO2, 320 rpm, 80% 
humidity
2.105
Main feed: 3% (day 3), 6% (days 5, 7, 10, 
14)




IgG1 Process 3 Cellvento
TM 
CHO-210
50 mL spin 
tubes
37 °C, 5% CO2, 320 rpm, 80% 
humidity
3.105
Main feed: 6% (day 3, 5, 7, 10, 12)
Glucose adjusted on demand to 6 g/L
mAb4 CHOZN® IgG1 Process 4
Excell® 
Advanced
50 mL spin 
tubes
37 °C, 5% CO2, 200 rpm, 80% 
humidity
3.105
Main feed: 5% (day 3), 10% (day 6), 5% 
(day 8, 10)
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mAb2 - Cell line 2 - Process 2
LC-HC linkage (day 13)
Feed + cysteine 
(Ctrl)





mAb2 - Cell line 2 - Process 2
LC-HC linkage (day 13)
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mAb3- Cell line 3 - Process 3
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